[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633215":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":28,"responsibleParty":47,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Chemotherapy group",null,"Patients with triple-negative breast cancer who underwent neoadjuvant chemotherapy",{"label":13,"type":10,"description":14,"interventionNames":10},"Immunotherapy group","Patients with triple-negative breast cancer who underwent neoadjuvant Immunotherapy",[16],{"name":17,"affiliation":5,"role":18},"Jue Wang","STUDY_DIRECTOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Xiaoming Zha","CONTACT","008613952001278","njzhaxm@njmy.edu.cn",{"name":17,"role":22,"phone":26,"phoneExt":10,"email":27},"008618061695508","wangjue200011@njmu.edu.cn",[29],{"facility":30,"status":10,"city":31,"state":32,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"the First Affiliated Hospital of Nanjing Medical University","Nanjing","Jiangsu","China","CN",{"type":36,"coordinates":37},"Point",[38,39],118.77778,32.06167,{"lat":39,"lon":38},[42,46],{"name":43,"role":22,"phone":44,"phoneExt":10,"email":45},"Danni Shen","008618136311251","shendannidoct@163.com",{"name":17,"role":22,"phone":26,"phoneExt":10,"email":27},{"type":48,"investigatorFullName":17,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Prof.","100633215","comparison-of-chemotherapy-and-immunotherapy-in-neoadjuvant-therapy-for-tnbc-100633215",false,"NCT07523789","Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC","Analysis of the Efficacy and Influencing Factors of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for Triple-Negative Breast Cancer","Inclusion Criteria:\n\n* (1)The patient is aged ≥18 years;(2) Both the biopsy pathology and postoperative pathology confirm the diagnosis of triple-negative breast cancer; (3) The patient has undergone complete neoadjuvant therapy; (4) After neoadjuvant therapy, the patient underwent surgical treatment and has complete postoperative pathology results; (5) The patient's basic information is complete.\n\nExclusion Criteria:\n\n* (1) Bilateral breast cancer or distant metastasis; (2) History of previous malignant tumor or chemotherapy\u002Fimmunotherapy; (3) Required NST not completed or no surgical treatment after NST; (4) Lack of pathological evaluation results for biopsy specimens or postoperative specimens, or postoperative pathological results not being triple negative; (5) Unable to obtain characteristic patient information, such as age and tumor stage. (6) Change in regimen during neoadjuvant therapy; (7) Lost to follow-up patients.","FEMALE","18 Years",{"count":60,"type":61},201,"ESTIMATED","OBSERVATIONAL","This study is an observational study that retrospectively collects data of triple-negative breast cancer patients who received neoadjuvant therapy. It compares the bpCR rate, apCR rate, and tpCR rate of patients treated with chemotherapy or immunotherapy, in order to analyze the efficacy and influencing factors of chemotherapy and immunotherapy in neoadjuvant therapy for triple-negative breast cancer.",[65],"TNBC, Triple Negative Breast Cancer","NOT_YET_RECRUITING","2026-04-05",{"date":69,"type":70},"2026-04-13","ACTUAL",{"date":72,"type":61},"2026-05-01",{"date":74,"type":61},"2027-05-01",{"name":5,"class":6},1]